Form 4: NeoGenomics CEO Christopher M. Smith Reports Stock Transactions
SEC Form 4 Filing
CEO Christopher M. Smith reports the vesting and conversion of restricted stock units, along with associated tax withholding, impacting his beneficial ownership of NeoGenomics stock.
Summary
- On February 23, 2025, Christopher M. Smith, CEO of NeoGenomics, reported transactions involving the company's stock.
- 57,413 restricted stock units were converted into common stock.
- 14,067 shares were disposed of to cover tax withholding obligations related to the vesting of restricted stock units.
- Following these transactions, Mr. Smith beneficially owns 641,585 shares of NeoGenomics common stock.
- Mr. Smith also holds various stock options and performance stock units with different vesting schedules and performance criteria.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about executive stock ownership.
Future Outlook
The document does not contain specific forward-looking statements beyond the vesting schedules of the stock options and restricted/performance stock units.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the holdings and transactions of key company personnel.
Comparison to Industry Standards
- Executive compensation packages often include a mix of salary, stock options, restricted stock units, and performance-based incentives.
- Vesting schedules for stock options and restricted stock units are typically three to four years, aligning executive interests with long-term company performance.
- Performance stock units are often tied to specific financial or operational metrics, such as revenue growth or share price appreciation, similar to the metrics described in this filing.
- Companies like Exact Sciences and Guardant Health also utilize similar equity-based compensation strategies for their executives.
Stakeholder Impact
- The filing provides transparency to shareholders regarding executive compensation and alignment of interests.
- Employees may be interested in the details of executive compensation packages.
- The transactions have a minor impact on the overall share structure of the company.
Key Dates
| Date | Description |
|---|---|
| 08/15/2022 | Mr. Smith was granted 694,444 stock options, vesting ratably over four years. |
| 05/11/2023 | Mr. Smith was granted 269,841 stock options, vesting ratably over three years. |
| 05/11/2023 | Mr. Smith was granted 144,190 restricted stock units, vesting ratably over three years. |
| 05/11/2026 | Performance stock units granted on May 11, 2023, may vest. |
| 02/23/2024 | Mr. Smith was granted 287,940 stock options, vesting ratably over three years. |
| 02/23/2024 | Mr. Smith was granted 172,239 restricted stock units, vesting ratably over three years. |
| 02/23/2024 | Mr. Smith was granted 172,240 performance stock units, vesting based on share and revenue growth. |
| 02/23/2025 | Restricted stock units converted to common stock; shares disposed of for tax obligations. |
| 02/25/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.